Our data suggest that PROG might have therapeutic possibilities for clinical subgroups of FTD with Tau pathology, because low levels of the endogenous neurosteroid were also associated with increased risk of CBS (Table 1). The gene discussed is MAPT; the disease is frontotemporal dementia.